Borthwick John
Known title: DirectorCIK: 0001972409
Borthwick John's purchase track record
Borthwick John has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/10/2024 | SRTA | $23K | -3.0% | +52.6% | +12.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SRTA | ▲ Buy | Grant | 35,534 | $0 | 8/1/2025 | View on chart |
| SRTA | ▲ Buy | Option Exercise | 104,388 | $32K | 12/13/2024 | View on chart |
| SRTA | ▼ Sell | Open Market | 78,291 | $313K | 12/13/2024 | View on chart |
| SRTA | ▲ Buy | Grant | 15,703 | $0 | 8/9/2024 | View on chart |
| SRTA | ▲ Buy | Grant | 42,826 | $0 | 8/9/2024 | View on chart |
| SRTA | ▲ Buy | Open Market | 7,743 | $23K | 6/10/2024 | View on chart |
| SRTA | ▲ Buy | Grant | 12,471 | $0 | 8/8/2023 | View on chart |
| SRTA | ▲ Buy | Grant | 1,247 | $0 | 8/8/2023 | View on chart |
| SRTA | ▲ Buy | Grant | 31,178 | $0 | 8/8/2023 | View on chart |
| SRTA | ▲ Buy | Grant | 31,178 | $0 | 8/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Strata Critical Medical Releases Q2 2026 Earnings Call Transcript
Strata Critical Medical released the transcript of its Q2 2026 earnings call. The discussion covers revenue, operating expenses, and guidance for the next quarter. The release gives investors a clearer view of the company’s financial performance and outlook, which may affect trading near its support level.
Strata Critical Medical Releases Q2 2026 Earnings Call Transcript. Strata Critical Medical released the transcript of its Q2 2026 earnings call. The discussion covers revenue, operating expenses, and guidance for the next quarter. The release gives investors a clearer view of the company’s financial performance and outlook, which may affect trading near its support level.